Aravive (NASDAQ:ARAV) Downgraded to “Hold” at ValuEngine

ValuEngine downgraded shares of Aravive (NASDAQ:ARAV) from a buy rating to a hold rating in a research report sent to investors on Thursday, ValuEngine reports.

ARAV has been the subject of several other reports. Wedbush initiated coverage on shares of Aravive in a research note on Monday, April 8th. They issued an outperform rating and a $14.00 target price for the company. Zacks Investment Research downgraded shares of Aravive from a buy rating to a hold rating in a research note on Wednesday, July 10th. Finally, Piper Jaffray Companies initiated coverage on shares of Aravive in a research note on Monday, May 13th. They issued an overweight rating and a $10.00 target price for the company.

NASDAQ:ARAV traded down $0.04 during mid-day trading on Thursday, hitting $6.56. The stock had a trading volume of 23,979 shares, compared to its average volume of 23,755. Aravive has a twelve month low of $3.07 and a twelve month high of $12.00. The stock has a 50 day simple moving average of $5.81. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.78 and a current ratio of 7.78.

Aravive (NASDAQ:ARAV) last issued its earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.44. The firm had revenue of $1.70 million during the quarter. As a group, equities analysts forecast that Aravive will post -2.19 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp bought a new position in Aravive in the 4th quarter valued at about $54,000. California Public Employees Retirement System bought a new position in Aravive in the 4th quarter valued at about $57,000. D. E. Shaw & Co. Inc. bought a new position in Aravive in the 4th quarter valued at about $73,000. Deutsche Bank AG bought a new position in Aravive in the 4th quarter valued at about $78,000. Finally, Millennium Management LLC bought a new position in Aravive in the 4th quarter valued at about $86,000. 27.57% of the stock is currently owned by hedge funds and other institutional investors.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Recommended Story: What is net income?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.